Lipigon Pharmaceuticals AB (LPGO) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.806x

Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has a cash flow conversion efficiency ratio of -0.806x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-6.38 Million ≈ $-686.81K USD) by net assets (Skr7.91 Million ≈ $851.67K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LPGO days of operational coverage to measure how many days the company can operate on defensive assets alone.

Lipigon Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2018–2025)

This chart illustrates how Lipigon Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lipigon Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Premier African Minerals Ltd LSE:PREM	-0.001x
Marechale Capital Plc LSE:MAC	-0.059x
TAURUS GOLD CORP. F:W1N	N/A
Wishbone Gold Plc LSE:WSBN	-0.187x
Livento Group Inc. NASDAQ:NUGND	0.001x
AYURCANN HOLDINGS CORP. F:3ZQ0	0.263x
Delta Electronics (Thailand) Public Company Limited F:DLS	0.028x
Velocity Composites plc LSE:VEL	0.042x

Annual Cash Flow Conversion Efficiency for Lipigon Pharmaceuticals AB (2018–2025)

The table below shows the annual cash flow conversion efficiency of Lipigon Pharmaceuticals AB from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Lipigon Pharmaceuticals AB stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr7.91 Million ≈ $851.67K	Skr-35.77 Million ≈ $-3.85 Million	-4.520x	-41.57%
2024-12-31	Skr7.76 Million ≈ $835.21K	Skr-24.78 Million ≈ $-2.67 Million	-3.193x	-534.28%
2023-12-31	Skr28.44 Million ≈ $3.06 Million	Skr-14.32 Million ≈ $-1.54 Million	-0.503x	+94.80%
2022-12-31	Skr3.87 Million ≈ $416.58K	Skr-37.47 Million ≈ $-4.03 Million	-9.679x	-529.59%
2021-12-31	Skr22.96 Million ≈ $2.47 Million	Skr-35.30 Million ≈ $-3.80 Million	-1.537x	-131.41%
2020-12-31	Skr12.98 Million ≈ $1.40 Million	Skr-8.62 Million ≈ $-928.19K	-0.664x	+74.08%
2019-12-31	Skr2.17 Million ≈ $233.42K	Skr-5.56 Million ≈ $-598.24K	-2.563x	-166.14%
2018-12-31	Skr-842.00K ≈ $-90.61K	Skr-3.26 Million ≈ $-351.15K	3.875x	--

About Lipigon Pharmaceuticals AB

ST:LPGO Sweden Biotechnology

Market Cap

$97.81K

Skr908.90K SEK

Market Cap Rank

#31293 Global

#747 in Sweden

Share Price

Skr0.00

Change (1 day)

-44.44%

52-Week Range

Skr0.00 - Skr0.19

All Time High

Skr10.15